RSS Updates
Email Updates
Nucryst Pharmaceuticals (NCST) is up over 100% to $4.40 on news that the FDZ cleared its antimicrobial cream containing the compound NPI 32101 Of course, there was no revenue forecast attached to the news.
Nucryst investors have had a frightening ride over the last year. Shares were at $16 a year ago. They were below $2 in early July.
The stock is another example of the craziness attached to micro-cap pharma stocks. In the last quarter, the company lost almost $2 million on just over $5 million in revenue. Today it has an $80 million market cap.
Douglas A. McIntyre
Buzz up!
Digg
Fark
Facebook
Tip'd
